Surgery, octreotide, temozolomide, bevacizumab, radiotherapy and pegvisomant treatment of an AIP mutation positive child
The Journal of clinical endocrinology and metabolism, 2019.
Multimodal treatment with surgery, octreotide-LAR, radiotherapy, temozolomide, bevacizumab and pegvisomant can control genetically driven aggressive childhood-onset somatotrophinomas.
Full Text (Upload PDF)
PPT (Upload PPT)